GeoVax Labs (GOVX) 10-Q 13 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 13, 2019
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	0000832489
Trading Symbol	govx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		2,477,584
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 216,411	$ 259,701
Grant funds and other receivables	64,246	121,814
Prepaid expenses and other current assets	39,139	238,189
Total current assets	319,796	619,704
Property and equipment, net (Note 5)	11,827	11,350
Deposits	11,010	11,010
Total assets	342,633	642,064
Current liabilities:
Accounts payable	116,207	125,859
Accrued expenses (Note 6)	1,510,268	1,238,552
Current portion of notes payable (Note 7)	12,500	260,420
Total current liabilities	1,638,975	1,624,831
Note payable, net of current portion (Note 7)	32,291	39,580
Total liabilities	1,671,266	1,664,411
Commitments (Note 8)
Stockholders’ equity (deficiency):
Preferred Stock, $.01 par value: Authorized shares – 10,000,000 Issued and outstanding shares – 3,402 and 3,450 at June 30, 2019 and December 31, 2018, respectively (Note 9)	2,337,867	1,971,333
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 813,916 and 437,807 at June 30, 2019 and December 31, 2018, respectively	814	438
Additional paid-in capital	38,165,172	37,482,766
Accumulated deficit	(41,832,486)	(40,476,884)
Total stockholders’ equity (deficiency)	(1,328,633)	(1,022,347)
Total liabilities and stockholders’ equity (deficiency)	$ 342,633	$ 642,064

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	3,402	3,450
Preferred stock, shares outstanding (in shares)	3,402	3,450
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	813,916	437,807
Common stock, shares outstanding (in shares)	813,916	437,807

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Grant and collaboration revenue	$ 209,941	$ 93,265	$ 574,173	$ 314,564
Operating expenses:
Research and development	451,227	372,202	1,006,945	859,196
General and administrative	412,650	359,197	922,714	716,425
Total operating expenses	863,877	731,399	1,929,659	1,575,621
Loss from operations	(653,936)	(638,134)	(1,355,486)	(1,261,057)
Other income (expense):
Interest income	881	1,716	2,105	3,034
Interest expense	(1,093)	(625)	(2,221)	(833)
Total other income (expense)	(212)	1,091	(116)	2,201
Net loss	$ (654,148)	$ (637,043)	$ (1,355,602)	$ (1,258,856)
Basic and diluted:
Loss per common share (in dollars per share)	$ (1.01)	$ (2.05)	$ (2.37)	$ (4.50)
Weighted averages shares outstanding (in shares)	649,486	310,419	571,032	279,551

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	3,670	213,474
Balance at Dec. 31, 2017	$ 1,899,085	$ 213	$ 35,696,435	$ (37,916,790)	$ (321,057)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	600
Sale of convertible preferred stock for cash and cancellation of note payable	$ 590,000				590,000
Conversion of preferred stock to common stock (in shares)	(450)	60,000
Conversion of preferred stock to common stock	$ (441,000)	$ 60	440,940
Stock option expense			23,978		23,978
Net loss				(621,813)	(621,813)
Issuance of common stock for services (in shares)		10,000
Issuance of common stock for services		$ 10	199,990		200,000
Balance (in shares) at Mar. 31, 2018	3,820	283,474
Balance at Mar. 31, 2018	$ 2,048,085	$ 283	36,361,343	(38,538,603)	(128,892)
Balance (in shares) at Dec. 31, 2017	3,670	213,474
Balance at Dec. 31, 2017	$ 1,899,085	$ 213	35,696,435	(37,916,790)	(321,057)
Net loss					$ (1,258,856)
Issuance of common stock for services (in shares)					10,000
Balance (in shares) at Jun. 30, 2018	3,475	329,474
Balance at Jun. 30, 2018	$ 1,709,985	$ 329	36,722,618	(39,175,646)	$ (742,714)
Balance (in shares) at Mar. 31, 2018	3,820	283,474
Balance at Mar. 31, 2018	$ 2,048,085	$ 283	36,361,343	(38,538,603)	(128,892)
Conversion of preferred stock to common stock (in shares)	(345)	46,000
Conversion of preferred stock to common stock	$ (338,100)	$ 46	338,054
Stock option expense			23,221		23,221
Net loss				(637,043)	$ (637,043)
Issuance of common stock for services (in shares)					0
Balance (in shares) at Jun. 30, 2018	3,475	329,474
Balance at Jun. 30, 2018	$ 1,709,985	$ 329	36,722,618	(39,175,646)	$ (742,714)
Balance (in shares) at Dec. 31, 2018	3,450	437,807
Balance at Dec. 31, 2018	$ 1,971,333	$ 438	37,482,766	(40,476,884)	(1,022,347)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	500
Sale of convertible preferred stock for cash and cancellation of note payable	$ 404,250		85,750		490,000
Conversion of preferred stock to common stock (in shares)	(767)	118,280
Conversion of preferred stock to common stock	$ (303,475)	$ 118	303,357
Fractional shares issuable upon reverse stock split (in shares)		402
Fractional shares issuable upon reverse stock split
Stock option expense			26,652		26,652
Net loss				(701,454)	(701,454)
Balance (in shares) at Mar. 31, 2019	3,183	556,489
Balance at Mar. 31, 2019	$ 2,072,108	$ 556	37,898,525	(41,178,338)	(1,207,149)
Balance (in shares) at Dec. 31, 2018	3,450	437,807
Balance at Dec. 31, 2018	$ 1,971,333	$ 438	37,482,766	(40,476,884)	(1,022,347)
Net loss					$ (1,355,602)
Issuance of common stock for services (in shares)					4,127
Balance (in shares) at Jun. 30, 2019	3,402	813,916
Balance at Jun. 30, 2019	$ 2,337,867	$ 814	38,165,172	(41,832,486)	$ (1,328,633)
Balance (in shares) at Mar. 31, 2019	3,183	556,489
Balance at Mar. 31, 2019	$ 2,072,108	$ 556	37,898,525	(41,178,338)	(1,207,149)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	500
Sale of convertible preferred stock for cash and cancellation of note payable	$ 438,700		61,300		500,000
Conversion of preferred stock to common stock (in shares)	(281)	253,300
Conversion of preferred stock to common stock	$ (172,941)	$ 254	172,687
Fractional shares issuable upon reverse stock split (in shares)
Fractional shares issuable upon reverse stock split
Stock option expense			26,664		26,664
Net loss				(654,148)	$ (654,148)
Issuance of common stock for services (in shares)		4,127			4,127
Issuance of common stock for services		$ 4	5,996		$ 6,000
Balance (in shares) at Jun. 30, 2019	3,402	813,916
Balance at Jun. 30, 2019	$ 2,337,867	$ 814	$ 38,165,172	$ (41,832,486)	$ (1,328,633)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (1,355,602)	$ (1,258,856)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,795	9,930
Stock-based compensation expense	258,396	132,913
Changes in assets and liabilities:
Grant funds and other receivables	57,568	59,758
Prepaid expenses and other current assets	(30)	41,695
Accounts payable and accrued expenses	262,064	252,802
Total adjustments	581,793	497,098
Net cash used in operating activities	(773,809)	(761,758)
Cash flows from investing activities:
Purchase of property and equipment	(4,272)
Net cash used in investing activities	(4,272)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	740,000	590,000
Proceeds from issuance of note payable		50,000
Principal repayment of note payable	(5,209)
Net cash provided by financing activities	734,791	640,000
Net decrease in cash and cash equivalents	(43,290)	(121,758)
Cash and cash equivalents at beginning of period	259,701	312,727
Cash and cash equivalents at end of period	$ 216,411	$ 190,969

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member]
Convertible note, shares issued (in shares)	250
Convertible note, value	$ 250,000
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,563
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,200
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of stock, shares issued (in shares)	2,763
Conversion of Series C Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	587
Conversion of stock, shares issued (in shares)	78,280
Conversion of Series F Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	461	293,300
Conversion of stock, shares issued (in shares)	293,300
Conversion From Series D Convertible Preferred Stock To Common Stock [Member]
Convertible preferred stock (in shares)		795
Conversion of stock, shares issued (in shares)		106,000

Note 1 - Description of Busines

Note 1 - Description of Business	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases using a novel vector vaccine platform (Modified Vaccinia Ankara Virus-Like Particle, or “MVA-VLP”). Our recombinant MVA vector expresses target proteins on highly immunogenic VLPs in the person being vaccinated, resulting in durable immune responses while providing the safety characteristics of the replication-defective MVA vector. Important attributes of GeoVax vaccines include single dose, no Our current development programs are focused on preventive and therapeutic vaccines against Human Immunodeficiency Virus (HIV); preventive vaccines against hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa fever), Zika virus and malaria; a therapeutic vaccine for chronic hepatitis B virus infections; and preventive and therapeutic vaccines for multiple solid tumor cancers. Our most advanced vaccine program is focused on the clade B subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan and Australia; this program is currently undergoing human clinical trials. Our corporate strategy is to improve health to patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in metropolitan Atlanta, Georgia.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Basis of Accounting [Text Block]	2. The accompanying condensed consolidated financial statements at June 30, 2019 three six June 30, 2019 2018 not 10 December 31, 2018. not As described in Note 10, April 30, 2019, one five hundred Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources, government funding commitments, and equity funding commitments discussed in Note 13 first 2020. not may not

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. We disclosed in Note 2 10 December 31, 2018 no 10 In February 2016, No. 2016 02, Leases 2016 02 2016 02 not 12 12 2016 02 January 1, 2019; no 12 8 There have been no six June 30, 2019, 10 December 31, 2018,

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled 376,130 351,684 three six June 30, 2019, 51,270 51,155 three six June 30, 2018,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2019 December 31, 2018: June 30, 2019 December 31, 2018 Laboratory equipment $ 534,578 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 678,868 674,596 Accumulated depreciation and amortization (667,041 ) (663,246 ) Property and equipment, net $ 11,827 $ 11,350

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2019 December 31, 2018: June 30, 2019 December 31, 2018 Accrued management salaries $ 1,128,425 $ 924,509 Accrued directors’ fees 361,470 295,670 Other accrued expenses 20,373 18,373 Total accrued expenses $ 1,510,268 $ 1,238,552

Note 7 - Notes Payable

Note 7 - Notes Payable	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	7. On February 28, 2018, five $50,000. 5%, second $6,250 2019, $12,500 2020, 2021 2022, $2,083 2023. three six June 30, 2019 $586 $1,207, $625 $833, 2018. On December 27, 2018, two $250,000. February 2019, 9

Note 8 - Commitments

Note 8 - Commitments	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. Lease Agreement We lease approximately 8,400 December 31, 2019, December 31, 2022. three six June 30, 2019 $40,316 $80,633, $39,136 $78,273, 2018. $80,633 2019. one 90 Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of June 30, 2019, $459,000 2019.

Note 9 - Preferred Stock

Note 9 - Preferred Stock	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	9. Prefer red Stock Summary We are authorized to issue up to 10,000,000 $.01 may one June 30, 2019 December 31, 2018. $1,000 three six June 30, 2019 2018 June 30, 2019 December 31, 2018 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 76,095 100 76,095 Series C Convertible Preferred Stock - - 2,150 705,238 Series E Convertible Preferred Stock - - 1,200 1,190,000 Series F Convertible Preferred Stock 2,302 1,418,822 - - Series G Convertible Preferred Stock 1,000 842,950 - - Total 3,402 2,337,867 3,450 1,971,333 Series B Preferred Stock During the three six June 30, 2019 2018, no June 30, 2019, 100 may $175 Series C Preferred Stock During January February 2019, 587 78,280 February 2019, 1,563 three six June 30, 2018, no Series D Preferred Stock During the three six June 30, 2018, 345 795 46,000 106,000 June 30, 2019, no Series E Preferred Stock In March 2018, 600 $590,000. September 2018, 600 $600,000. February 2019, 1,200 Series F Preferred Stock On February 18, 2019, 2,763 $1,000 no not $7.50 90% may, three six June 30, 2019, 281 461 253,300 293,300 June 30, 2019, 2,302 Series G Preferred Stock On February 25, 2019, 1,000 $1.0 three $1,000 no not $7.50 90% may, At the first February 26, 2019, 500 $250,000 7 $250,000. first 33,334 $7.50 six five first may, second third April 26 June 19, 2019, 500 $500,000 66,668 June 30, 2019, 1,000

Note 10 - Common Stock and Stoc

Note 10 - Common Stock and Stock-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Reverse Stock Split Following approval by our shareholders at a meeting held on April 15, 2019, April 30, 2019, one five hundred Common Stock Transactions As discussed in Note 9, three six June 30, 2019, 253,300 371,580 three six June 30, 2018, 46,000 106,000 During the three six June 30, 2019, 4,127 three six June 30, 2018, 0 10,000 Stock Options During the six June 30, 2019, no June 30, 2019, 29,441 $53.19/share 13,585 $93.92/share Stock Purchase Warrants During the six June 30, 2019, 100,002 June 30, 2019, 294,302 $7.50/share 194,300 $7.50/share Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $26,664 $53,316 three six June 30, 2019, $23,221 $47,199, 2018. June 30, 2019, $157,067 1.9 During the three six June 30, 2019 $78,509 $205,080, $57,143 $85,714, 2018.

Note 11 - Income Taxes

Note 11 - Income Taxes	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Because of our historically significant net operating losses, we have not 382

Note 12 - Grants and Collaborat

Note 12 - Grants and Collaboration Revenue	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12. We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three six June 30, 2019, $184,938 $539,257, $93,265 $309,564, 2018. June 30, 2019, $2,049,990 2019 2020. During the three six June 30, 2019, $25,003 $34,916, third $5,000 2018.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	13. Stock Transactions On July 16, 2019, 3,257 $1,000 no not $7.50 80% ten may, On July 24, 2019, 700 $700,000. $1,000 no not $7.50 80% ten may, During July August 2019, 46 88,400 171 1,737,441 August 2019, 37,827

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2019 December 31, 2018 Laboratory equipment $ 534,578 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 678,868 674,596 Accumulated depreciation and amortization (667,041 ) (663,246 ) Property and equipment, net $ 11,827 $ 11,350

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2019 December 31, 2018 Accrued management salaries $ 1,128,425 $ 924,509 Accrued directors’ fees 361,470 295,670 Other accrued expenses 20,373 18,373 Total accrued expenses $ 1,510,268 $ 1,238,552

Note 9 - Preferred Stock (Table

Note 9 - Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Preferred Stock [Table Text Block]	June 30, 2019 December 31, 2018 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 76,095 100 76,095 Series C Convertible Preferred Stock - - 2,150 705,238 Series E Convertible Preferred Stock - - 1,200 1,190,000 Series F Convertible Preferred Stock 2,302 1,418,822 - - Series G Convertible Preferred Stock 1,000 842,950 - - Total 3,402 2,337,867 3,450 1,971,333

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Apr. 30, 2019
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	500

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	376,130	51,270	351,684	51,155

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Property and equipment, gross	$ 678,868	$ 674,596
Accumulated depreciation and amortization	(667,041)	(663,246)
Property and equipment, net	11,827	11,350
Laboratory Equipment [Member]
Property and equipment, gross	534,578	530,306
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accrued management salaries	$ 1,128,425	$ 924,509
Accrued directors’ fees	361,470	295,670
Other accrued expenses	20,373	18,373
Total accrued expenses	$ 1,510,268	$ 1,238,552

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Feb. 28, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 27, 2018
Proceeds from Notes Payable, Total					$ 50,000
Interest Expense, Total		$ 1,093	$ 625	2,221	833
Term Notes [Member]
Debt Instrument, Face Amount						$ 250,000
Senior Notes [Member]
Debt Instrument, Term	5 years
Proceeds from Notes Payable, Total	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year		6,250		6,250
Long-term Debt, Maturities, Repayments of Principal in Year Two		12,500		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Three		12,500		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Four		12,500		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Five		2,083		2,083
Interest Expense, Total		$ 586	$ 625	$ 1,207	$ 833

Note 8 - Commitments (Details T

Note 8 - Commitments (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2019USD ($)ft²	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)ft²	Jun. 30, 2018USD ($)
Area of Real Estate Property | ft²	8,400		8,400
Operating Leases, Rent Expense, Total	$ 40,316	$ 39,136	$ 80,633	$ 78,273
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 80,633		$ 80,633
Lessee, Operating Lease, Renewal Term	1 year		1 year
Unrecorded Unconditional Purchase Obligation, Total	$ 459,000		$ 459,000

Note 9 - Preferred Stock (Detai

Note 9 - Preferred Stock (Details Textual) - USD ($)	Jun. 19, 2019	Apr. 26, 2019	Feb. 26, 2019	Feb. 25, 2019	Feb. 18, 2019	Feb. 28, 2019	Sep. 30, 2018	Mar. 31, 2018	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Preferred Stock, Shares Authorized										10,000,000		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share										$ 0.01		$ 0.01		$ 0.01
Preferred Stock, Shares Outstanding, Ending Balance										3,402		3,402		3,450
Series I Warrants [Member]
Convertible Preferred Stock and Related Warrants Issued			33,334
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 7.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			66,668
Series G Warrants [Member]
Warrants and Rights Outstanding, Term			5 years
Series G Convertible Preferred Stock and Related Warrants [Member]
Convertible Preferred Stock and Related Warrants, Authorized				1,000
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum	$ 500,000	$ 500,000	$ 250,000	$ 1,000,000
Convertible Preferred Stock and Related Warrants Issued	500	500	500
Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted									587			587
Conversion of Stock, Shares Issued									78,280			78,280
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted						1,563						1,563
Conversion of Series D Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted											345		795
Conversion of Stock, Shares Issued											46,000		106,000
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted						1,200						1,200
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted										281	253,300	461	293,300
Conversion of Stock, Shares Issued												293,300
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share										$ 1,000		$ 1,000
Conversion of Stock, Shares Converted										0	0	0	0
Preferred Stock, Shares Outstanding, Ending Balance										100		100		100
Convertible Preferred Stock, Conversion Price1										$ 175		$ 175
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share										$ 1,000		$ 1,000
Conversion of Stock, Shares Converted											0		0
Preferred Stock, Shares Outstanding, Ending Balance														2,150
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance										0		0
Series E Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share										$ 1,000		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance														1,200
Stock Issued During Period, Shares, New Issues							600	600
Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost							$ 600,000	$ 590,000
Series F Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share					$ 1,000					$ 1,000		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance										2,302		2,302
Convertible Preferred Stock, Conversion Price1					$ 7.50
Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock					2,763
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock					90.00%
Series G Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share				$ 1,000						$ 1,000		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance										1,000		1,000
Convertible Preferred Stock, Conversion Price1				$ 7.50
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock				90.00%

Note 9 - Preferred Stock - Pref

Note 9 - Preferred Stock - Preferred Stock Summary (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, shares outstanding (in shares)	3,402	3,450
Preferred Stock	$ 2,337,867	$ 1,971,333
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	100	100
Preferred Stock	$ 76,095	$ 76,095
Series C Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)		2,150
Preferred Stock		$ 705,238
Series E Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)		1,200
Preferred Stock		$ 1,190,000
Series F Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	2,302
Preferred Stock	$ 1,418,822
Series G Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	1,000
Preferred Stock	$ 842,950

Note 10 - Common Stock and St_2

Note 10 - Common Stock and Stock-based Compensation (Details Textual)	Apr. 30, 2019	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2018USD ($)shares	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2018USD ($)shares
Stock Issued During Period, Shares, Issued for Services		4,127	0	4,127	10,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		29,441		29,441
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares		$ 53.19		$ 53.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number		13,585		13,585
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares		$ 93.92		$ 93.92
Share-based Payment Arrangement, Expense | $		$ 26,664	$ 23,221	$ 53,316	$ 47,199
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $		157,067		$ 157,067
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				1 year 328 days
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $		$ 78,509	$ 57,143	$ 205,080	$ 85,714
Common Stock Purchase Warrants [Member]
Class Of Warrant Or Right Issued During Period				100,002
Class of Warrant or Right, Outstanding		294,302		294,302
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price | $ / shares		$ 7.50		$ 7.50
Class Of Warrant Or Right Exercisable Number		194,300		194,300
Class Of Warrant Or Right Exercisable Weighted Average Exercise Price | $ / shares		$ 7.50		$ 7.50
Conversion from Series C and F Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued		253,300		371,580
Conversion of Series D Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued			46,000		106,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	500

Note 12 - Grants and Collabor_2

Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue from Contract with Customer, Including Assessed Tax	$ 209,941	$ 93,265	$ 574,173	$ 314,564
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	184,938	93,265	539,257	309,564
Unused Grant Funds	2,049,990		2,049,990
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 25,003	$ 5,000	$ 34,916	$ 5,000

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	Aug. 12, 2019	Jul. 24, 2019	Jul. 16, 2019	Jul. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Preferred Stock, Par or Stated Value Per Share					$ 0.01		$ 0.01		$ 0.01
Stock Issued During Period, Shares, Issued for Services					4,127	0	4,127	10,000
Subsequent Event [Member]
Stock Issued During Period, Shares, Issued for Services	37,827
Subsequent Event [Member] | Series H Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share			$ 1,000
Convertible Preferred Stock, Conversion Price1			$ 7.50
Subsequent Event [Member] | Series I Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 1,000
Convertible Preferred Stock, Conversion Price1		$ 7.50
Stock Issued During Period, Shares, New Issues		700
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 700,000
Conversion from Series F and Series G Preferred Stock to Series H Preferred Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Issued			3,257
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued							293,300
Conversion of Stock, Shares Converted					281	253,300	461	293,300
Conversion of Series F Preferred Stock Into Common Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Issued				88,400
Conversion of Stock, Shares Converted				46
Conversion of Series H Preferred Stock Into Common Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Issued	1,737,441
Conversion of Stock, Shares Converted	171